H.C. Wainwright raised MLTX target to $45 after FDA alignment. The stock now faces an 18-month wait until the BLA filing in late September 2026, with cash runway into 2027.
H.C. Wainwright raised its price target on MoonLake Immunotherapeutics (NASDAQ:MLTX) to $45 from $40 on May 11, reaffirming a Buy rating. The revision followed the company's final pre-application discussions with the FDA for sonelokimab, its nanobody-based therapy for hidradenitis suppurativa. The regulatory alignment reduces clinical risk. The better market read is that the stock now faces an 18-month wait until a binary FDA acceptance decision, with the timeline itself becoming the dominant risk factor.
MoonLake held a successful pre-BLA meeting with the FDA on April 1. The company confirmed alignment on its biologics license application submission strategy, proposed labeling approach, and use of data from the MIRA and VELA-TEEN studies. The BLA filing for sonelokimab is scheduled for late September 2026, with potential FDA acceptance anticipated by end of November 2026. That timeline creates a specific exposure for MLTX shareholders. Between now and late 2026, the stock will trade on interim data updates, competitor news in the IL-17 space, and general biotech sector sentiment. The pre-BLA alignment removes one layer of regulatory uncertainty. The long gap between today and the filing date means the stock could drift without a near-term catalyst. The risk is not that the FDA rejects the application. It is that the market loses patience or that a competing therapy shifts the standard of care before sonelokimab reaches the market.
MoonLake ended the first quarter with $357.9 million in cash, cash equivalents, and short-term marketable securities. The company expects funding capacity into the end of 2027, and it has access to up to $400 million through its Hercules Capital debt agreement. That financial buffer reduces the risk of a dilutive equity raise before the BLA filing. The cash runway covers the sonelokimab program through FDA acceptance and into the early stages of a potential launch. The debt facility provides additional flexibility if the company needs to accelerate its Phase 3 program in psoriatic arthritis or expand into other indications. For broader context on how regulatory milestones affect biotech valuations, see our stock market analysis.
What would reduce the risk further: a steady cadence of clinical data updates from the psoriatic arthritis Phase 3 studies, or a partnership deal that validates sonelokimab's commercial potential before the FDA decision. What would make the risk worse: a delay in the BLA filing timeline, a safety signal in the ongoing studies, or a competitor achieving a superior efficacy or safety profile in hidradenitis suppurativa.
The next concrete marker is the BLA filing itself in late September 2026. Before that, any update from the Phase 3 psoriatic arthritis program could serve as an interim catalyst. The FDA acceptance decision in November 2026 is the first binary event that will determine whether sonelokimab moves toward approval or faces additional review cycles. For traders and investors tracking clinical-stage biotech, MLTX offers a clear regulatory path but a long wait. The stock's valuation will depend on how the market prices the probability of FDA acceptance and the eventual commercial opportunity. The cash position and debt facility provide a cushion. The timeline remains the dominant variable. Changes to the filing schedule or new data from the psoriatic arthritis studies are the next signals that could shift the risk-reward profile.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.